Fidaxomicin: A new fight against clostridium difficile-associated diarrhea
نویسندگان
چکیده
منابع مشابه
Fidaxomicin Use and Clinical Outcomes for Clostridium difficile–Associated Diarrhea
BACKGROUND Fidaxomicin has been scrutinized because of its high acquisition cost. Real-world experience is needed to determine whether fidaxomicin has value in patients with Clostridium difficile-associated diarrhea (CDAD) and certain risk factors. METHODS In this single-center, retrospective cohort study, patients 18 years or older with diarrheal symptoms and positive polymerase chain reacti...
متن کاملClostridium difficile-associated diarrhea.
At our hospital, the number of cases of Clostridium difficile-associated diarrhoea increased from 29 in 1993 to 210 in 1995. The case notes of 110 patients with C difficile-associated diarrhoea during the first 6 months of 1995 were analysed retrospectively. The majority of the patients (106) had received antibiotics before the onset of diarrhoea; 46 had received three or more different antibio...
متن کاملFidaxomicin for Clostridium difficile-Associated Diarrhoea
BACKGROUND Fidaxomicin is a macrocyclic antibiotic approved in 2011 by the US Food and Drug Administration for treatment of Clostridium difficile-associated diarrhoea (CDAD). OBJECTIVE Herein, we present an epidemiological method to estimate, on a case mix basis, and from the perspective of the US health system, the warranted (justifiable) price per day for fidaxomicin, as a percent of the wh...
متن کاملClostridium difficile – Associated Diarrhea Outbreaks
Sir—We read with interest the article by Pépin et al. [1], which reports that use of quinolones is a major risk factor for illness during an outbreak of Clostridium difficile–associated diarrhea (CDAD). These results confirm previous observations that quinolones and other antibiotics, such as third-generation cephalosporins, macrolides, broad-spectrumb-lactams, and aminoglycosides, are importan...
متن کاملFidaxomicin for Clostridium difficile Infection.
To the Editor: In their randomized study comparing fidaxomicin with vancomycin for Clostridium difficile infection, Louie et al. (Feb. 3 issue)1 found that substantially fewer patients in the fidaxomicin group had recurrences of C. difficile infection within 4 weeks after the conclusion of treatment. We recently reported on an observational study involving U.S. veterans in which the recurrence ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Muller Journal of Medical Sciences and Research
سال: 2014
ISSN: 0975-9727
DOI: 10.4103/0975-9727.135753